Ruolo dei contraccettivi orali nell’etiopatogenesi delle IBD
The Risk of Oral Contraceptives in the Etiology of Inflammatory Bowel Disease: A Meta-Analysis.Cornish JA, Tan E, Simillis C, Clark…
Approfondisci...
Meta-analisi: mesalamina vs balsalazide nell’UC
Comparison of Mesalazine and Balsalazide in Induction and Maintenance of Remission in Patients with Ulcerative Colitis: A Meta-Analysis. Rahimi R,…
UC: metodologie a confronto per l’individuazione di tessuto neoplastico
Endoscopic tri-modal imaging for surveillance in ulcerative colitis: randomised comparison of high-resolution endoscopy and autofluorescence imaging for neoplasia detection; and…
UC lieve-moderata : utilizzo del desametasone a rilascio eritrocitario
Erythrocyte-Mediated Delivery of Dexamethasone in Patients With Mild-to-Moderate Ulcerative Colitis, Refractory to Mesalamine: A Randomized, Controlled Study. Bossa F, Latiano…
Rifaximina nella terapia di mantenimento della pouchite
Rifaximin for maintenance therapy in antibiotic-dependent pouchitis. Shen B, Remzi FH, Lopez AR, Queener E. BMC Gastroenterol. 2008 Jun 23;8:26. …
Interferon-beta-1a sottocutaneo nel trattamento della colite ulcerosa
Clinical trial: a multicentre, randomized, double-blind, placebo-controlled, dose-finding, phase II study of interferon-beta-1a in moderately active ulcerative colitis..Pena-Rossi C, Schreiber…
Aferesi nel trattamento dell’UC
A Randomized, Double-Blind, Sham-Controlled Study of Granulocyte/Monocyte Apheresis for Active Ulcerative Colitis. Sands BE, Sandborn WJ, Feagan B, Löfberg R,…
Incidenza del MAP nel Crohn
Incidence of Mycobacterium avium subspecies paratuberculosis in a population-based cohort of patients with Crohn’s disease and control subjects. Bentley RW,…
Fattori di rischio per infezioni opportunistiche nelle IBD
Risk factors for opportunistic infections in patients with inflammatory bowel disease.Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein…
Omega-3 nella terapia di mantenimento del M.di Crohn: The EPIC study
Omega-3 free fatty acids for the maintenance of remission in Crohn disease: the EPIC Randomized Controlled Trials.Feagan BG, Sandborn WJ,…
Nuovi anticorpi per la diagnosi sierologica di IBD
Antiglycan antibodies as serological markers in the differential diagnosis of inflammatory bowel disease. Simondi D, Mengozzi G, Betteto S, Bonardi…
Immunosoppressione precoce vs management convenzionale nel crohn neodiagnosticato
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. D’Haens G, Baert…
Management dell’ anemia sideropenica nelle IBD
Guidelines on the diagnosis and management of iron deficiency and anemia in inflammatory bowel diseases. Gasche C, Berstad A, Befrits…
E’ possible la trasmissione delle IBD?
Inflammatory bowel disease–live transmission. Hecht GA. I N Engl J Med. 2008 Jan 31;358(5):528-30. Inflammatory bowel disease results from a…
La dieta potrebbe essere un trigger del Crohn
Ingested matter affects intestinal lesions in Crohn’s disease. Bartel G, Weiss I, Turetschek K, Schima W, P?sp?k A, Waldhoer T,…
Nuovo biomarker di severità nel Crohn
Autoantibodies against ubiquitination factor E4A (UBE4A) are associated with severity of Crohn’s disease. Sakiyama T, Fujita H, Tsubouchi H.Inflamm Bowel…
BMI: fattore predittivo di osteoporosi nelle IBD
Low body mass not vitamin D receptor polymorphisms predict osteoporosis in patients with inflammatory bowel disease.Noble CL, McCullough J, Ho…
Una nuova fomulazione di ferro EV per l’anemia nelle IBD
A Novel Intravenous Iron Formulation for Treatment of Anemia in Inflammatory Bowel Disease: The Ferric Carboxymaltose (FERINJECT((R))) Randomized Controlled Trial.…
IBD: nuovo marker di mancata risposta all’AZA
A 6-Thioguanine Nucleotide Threshold Level of 400 pmol/8 x 10(8) Erythrocytes Predicts Azathioprine Refractoriness in Patients With Inflammatory Bowel Disease…
MMX nuovo trial nell’UC
MMX(trade mark) mesalazine for the induction of remission of mild-to-moderately active ulcerative colitis: efficacy and tolerability in specific patient sub-populations.…
Trattamento con rosiglitazone nella CU : un RCT
Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial. Lewis JD, Lichtenstein GR, Deren JJ, Sands BE, Hanauer SB, Katz…
M. di Crohn all’esordio: meglio l’immunosoppressione combinata
Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn’s disease: an open randomised trial. D’Haens G, Baert…
CU in età pediatrica : più a rischio di attacchi severi?
Severe paediatric ulcerative colitis: incidence, outcomes and optimal timing for second-line therapy. Turner D, Walsh CM, Benchimol EI, Mann EH,…
